# Keymed Bio's Stapokibart Revenue Surges

> Keymed Bio's Stapokibart posts 660 million yuan in first three quarters, shares jump 10.51%.
- Title: Keymed Bio's Stapokibart Revenue Surges · BigGo Finance
- Summary: Keymed Bio's Stapokibart posts 660 million yuan in first three quarters, shares jump 10.51%. Keymed Bio's Stapokibart generated 660 million yuan in revenue…
- Keywords: keymed bio, stapokibart, kangyueda, chinese national medical products admini, atopic dermatitis, phase iii clinical data, finance, markets, Keymed, Bio's, Revenue, Surges
- Source: BigGo Finance — https://finance.biggo.com/news/5abd91bf-3143-461c-bd2b-5b61cb0fc116
- Author: BigGo Finance
- Published: 2026-10-16T03:55:09+00:00
- Read time: 1 min
- Topics: keymed bio, stapokibart, kangyueda, chinese national medical products admini, atopic dermatitis, phase iii clinical data, finance, markets
## Keymed Bio Announces Revenue
Keymed Bio reported its core product Kangyueda generated 660 million yuan in revenue for the first three quarters of 2026, up 227% year-over-year.
## Shares Surge 10.51%
The company's shares rose 10.51% to HK$84.15 (approximately $11) after the announcement.
## New Atopic Dermatitis Approval
China's National Medical Products Administration approved stapokibart for moderate-to-severe atopic dermatitis in adolescents.
## Clinical Results
Phase III data showed 73.9% EASI-75 response rate at week 18, significantly higher than placebo's 43.3%.
## Key takeaway

Keymed Bio's Stapokibart generated 660 million yuan in revenue for 2026 Q1-Q3, up 227% year-over-year, with shares rising 10.51%.